Danielle Bradbury - Mineralys Therapeutics Senior Assurance
| MLYS Stock | 11.87 0.83 7.52% |
Executive
Danielle Bradbury is Senior Assurance of Mineralys Therapeutics Common
| Address | 150 N. Radnor Chester Rd., Radnor, PA, United States, 19087 |
| Phone | 888 378 6240 |
| Web | https://mineralystx.com |
Mineralys Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2891) % which means that it has lost $0.2891 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4138) %, meaning that it created substantial loss on money invested by shareholders. Mineralys Therapeutics' management efficiency ratios could be used to measure how well Mineralys Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.3 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, Mineralys Therapeutics' Total Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 13.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Henry Pelish | Nuvalent | N/A | |
| Benjamin Lane | Nuvalent | N/A | |
| Matthew Saxon | Zoom Video Communications | N/A | |
| Cheree McAlpine | Zoom Video Communications | N/A | |
| Christine Bastian | Western Digital | N/A | |
| Carole Watkins | Cardinal Health | 54 | |
| Greg Holmes | Zoom Video Communications | N/A | |
| Janine Pelosi | Zoom Video Communications | 41 | |
| Aaron Alt | Cardinal Health | 51 | |
| Craig JD | The Joint Corp | 71 | |
| James Edwards | The Joint Corp | N/A | |
| John Soglia | Nuvalent | N/A | |
| Peter Andrew | Western Digital | N/A | |
| Chris Bitterman | Cumberland Pharmaceuticals | 59 | |
| David Orwasher | The Joint Corp | 58 | |
| Catherine Hall | The Joint Corp | 52 | |
| Perrin BS | Nuvalent | N/A | |
| Erin Gull | Cumberland Pharmaceuticals | N/A | |
| Robert Soderbery | Western Digital | 58 | |
| Lori Sundberg | Western Digital | 51 | |
| Xuedong Huang | Zoom Video Communications | N/A | |
Management Performance
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.29 |
Mineralys Therapeutics Leadership Team
Elected by the shareholders, the Mineralys Therapeutics' board of directors comprises two types of representatives: Mineralys Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mineralys. The board's role is to monitor Mineralys Therapeutics' management team and ensure that shareholders' interests are well served. Mineralys Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mineralys Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert McKean, Senior CMC | ||
| Adam Levy, CFO Secretary | ||
| Sarah Foster, Vice Resources | ||
| Danielle Bradbury, Senior Assurance | ||
| Jon Congleton, CEO Director | ||
| Cindy Berejikian, Executive Operations | ||
| Minji MBA, Chief Officer | ||
| Jessica Ibbitson, Senior Operations | ||
| Jeffrey Fellows, Senior Affairs | ||
| David MD, Chief Officer | ||
| MD MPH, Founder Chairman |
Mineralys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mineralys Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 352.55 M | ||||
| Shares Outstanding | 49.63 M | ||||
| Shares Owned By Insiders | 2.95 % | ||||
| Shares Owned By Institutions | 92.45 % | ||||
| Number Of Shares Shorted | 872.86 K | ||||
| Price To Book | 2.67 X | ||||
| EBITDA | (84.66 M) | ||||
| Net Income | (71.9 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics Common. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Mineralys Stock analysis
When running Mineralys Therapeutics' price analysis, check to measure Mineralys Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics is operating at the current time. Most of Mineralys Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics' price. Additionally, you may evaluate how the addition of Mineralys Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Mineralys Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mineralys Therapeutics. If investors know Mineralys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mineralys Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.99) | Return On Assets (0.29) | Return On Equity (0.41) |
The market value of Mineralys Therapeutics is measured differently than its book value, which is the value of Mineralys that is recorded on the company's balance sheet. Investors also form their own opinion of Mineralys Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mineralys Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mineralys Therapeutics' market value can be influenced by many factors that don't directly affect Mineralys Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mineralys Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mineralys Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mineralys Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.